Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations.
Affiliation
Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2011
Metadata
Show full item recordAbstract
Despite discrepant results on clinical utility, several trials are already prospectively randomizing non-small cell lung cancer (NSCLC) patients by ERCC1 status. We aimed to characterize the prognostic and predictive effect of ERCC1 by systematic review and meta-analysis.Citation
Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. 2011, 6 (10):e25164 PLoS ONEJournal
PloS OneDOI
10.1371/journal.pone.0025164PubMed ID
22022380Type
ArticleLanguage
enISSN
1932-6203ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0025164
Scopus Count
Related articles
- Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
- Authors: Xu TP, Shen H, Liu LX, Shu YQ
- Issue date: 2013 Sep 10
- Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
- Authors: Vilmar A, Sørensen JB
- Issue date: 2009 May
- ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
- Authors: Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q
- Issue date: 2012 Jun
- Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
- Authors: Yu D, Shi J, Sun T, Du X, Liu L, Zhang X, Lu C, Tang X, Li M, Xiao L, Zhang Z, Yuan Q, Yang M
- Issue date: 2012 Jun